NEW YORK – Inify Laboratories on Tuesday said it has partnered with researchers at Karolinska Institutet to improve prostate cancer diagnosis through artificial intelligence-driven image analysis.
Inify is a digital pathology service provider that uses an AI-supported workflow for cancer diagnostics. It offers the Inify Prostate test in Europe for prostate cancer diagnosis, which analyzes hematoxylin and eosin whole slide images of prostate biopsy samples and then predicts and outlines areas that are suspicious for cancer. Pathologists then review the results and make a diagnosis.
In the collaboration with Karolinska's ProMort program, Stockholm-based Inify will use its AI platform to annotate different prostate growth patterns in prostate biopsy tissue such as cribriform structures, perineural invasion, and reactive stroma. It will then use those patterns to train AI models to expedite prostate cancer diagnosis.
Within ProMort, researchers are analyzing prostate cancer biopsies in the hopes of identifying novel molecular features associated with prostate cancer death. They also aim to develop a new prognostic tool within the project by combining clinical variables with patients' outcomes.
"The ultimate ground truth for training diagnostic AI applications is patient outcome," Inify Chief Technology Officer Arto Järvinen said in a statement. "This research project presents a unique opportunity to find hitherto undetected or unverified correlations between histopathological features and patient outcomes."